Nilotinib post-liver transplantation for acute hepatic failure related to imatinib

Leukemia Research

Volumn 33, Issue 12, 2009, Pages

  Perini, Guilherme F ^a   Santos, Fabio P S ^a   Funke, Vaneuza ^b   Ruiz, Jefferson ^b   Neto, Ben Hur Ferraz ^a   Hamerschlak, Nelson ^a  

^a HOSPITAL ISRAELITA ALBERT EINSTEIN   (Brazil)

^b FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

Author keywords

Chronic myelogenous leukemia; Imatinib; Liver failure; Liver transplant; Nilotinib

Indexed keywords

BCR ABL PROTEIN; BCR ABL1 PROTEIN; IMATINIB; NILOTINIB; TACROLIMUS; UNCLASSIFIED DRUG;

ACUTE GRAFT REJECTION; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CADAVER DONOR; CASE REPORT; CHOLESTASIS; CHRONIC MYELOID LEUKEMIA; CYTOPENIA; DRUG DOSE INCREASE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEPATIC ENCEPHALOPATHY; HUMAN; JAUNDICE; LETTER; LIVER FAILURE; LIVER NECROSIS; LIVER TOXICITY; LIVER TRANSPLANTATION; MENTAL DISEASE; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LIVER FAILURE, ACUTE; LIVER TRANSPLANTATION; MIDDLE AGED; PIPERAZINES; PYRIMIDINES;

EID: 70249100937     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2009.06.012     Document Type: Letter

References (8)

1. Peggs K., and Mackinnon S. Imatinib mesylate: the new gold standard for treatment of chronic myeloid leukemia. N Engl J Med 348 (2003) 1048-1050
2. O'Brien S.G., Guilhot F., Goldman J.M., et al. International randomized study of interferon versus STI571 (IRIS) 7-year follow-up: sustained survival low rate of transformation and increased rate of major molecular response (MMR) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CMLCP) treated with imatinib (IM). Blood 112 (2008) 186 [Abstract]
3. Kantarjian H.M., Giles F., Gattermann N., et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 110 (2007) 3540-3546
4. Hensley M.L., and Ford J.M. Imatinib treatment: specific issues related to safety, fertility, and pregnancy. Semin Hematol 40 (2003) 21-25
5. Cross T.J.S., Bagot C., Portmann B., Wendon J., and Gillett D. Imatinib mesylate as a cause of acute liver failure. Am J Hematol 81 (2006) 189-192
6. Ridruejo E., Cacchione R., Villamil A.G., Marciano S., Gadano A.C., and Mandó O.G. Imatinib-induced fatal acute liver failure. World J Gastroenterol 28 13 (2007) 6608-6611
7. Ferrero D., Pogliani E.M., Rege-Cambrin G., et al. Corticosteroids can reverse severe imatinib-induced hepatotoxicity. Haematologica 91 (2006) ECR27
8. Jabbour E., Kantarjian H., Baccarani M., et al. Minimal cross-intolerance between nilotinib and imatinib in patients with imatinib-intolerant chronic myeloid leukemia in chronic phase (CML-CP) or accelerated phase (CML-AP). Blood 112 (2008) [Abstract 3215]